
Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

Spyridon Fortis, MD, from the division of pulmonary, critical care, and occupational medicine at the University of Iowa Hospital and Clinics.

Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

COPDGene data show bronchodilator response more accurately predicts FEV₁ decline and disease progression than polygenic risk scores, including among smokers with preserved spirometry.